Status:
COMPLETED
the Value of Sensory Index in Trigeminal Neuralgia
Lead Sponsor:
National Cancer Institute, Egypt
Conditions:
Pain, Chronic
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Interventional therapies for Trigeminal Neuralgia are of variable efficacy and safety, and have different results for different periods of time before the recurrence of symptoms. Interventional therap...
Detailed Description
Trigeminal neuralgia (TN) is defined by the International Headache Society (IHS) as "unilateral disorder characterized by brief electric shock-like pains, abrupt in onset and termination, and limited ...
Eligibility Criteria
Inclusion
- Patients with trigeminal neuralgia, diagnosed in accordance with the International Headache Society (7) and with a visual analogue score (VAS) for pain of at least 7 or more for a minimum of 3 months before the intervention .
- Patients on a stable analgesic regimen for 2 weeks (consisting of at least two analgesics, including anticonvulsants) before the intervention .
- Patients examined by use of MRI/A of the brain to exclude secondary neuralgia.
Exclusion
- Patients with severe mental or psychiatric disorders
- Patients with history of drug abuse, high intracranial tension and history of MVD, SGK, balloon compression, RF treatment, or glycerol injection
- The possibility of vascular loop compression and other causes of TN
Key Trial Info
Start Date :
May 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 15 2020
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT04864964
Start Date
May 1 2014
End Date
July 15 2020
Last Update
November 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute
Cairo, Egypt, 11796